China's innovative drugs going global are moving beyond one-off deals.

From bringing global innovation into China to multinational pharmaceutical companies actively seeking innovation within China; from single-asset licensing to co-development and long-term partnerships, what transformations are reshaping cross-border collaboration in China's innovative drug sector?

At the 2026 Zhangjiang Pharma Valley Conference and Shanghai International Biopharmaceutical Industry Week, Chen Jinglian, Head of Excellence & Innovation for Pfizer China, and Ren Feng, Co-CEO and Chief Scientific Officer of Insilico Medicine, joined a live broadcast to discuss how Chinese innovation is going global, as well as new opportunities and models for cross-border collaboration. Watch the highlights here →